Peter the Bridge, Saint Petersburg, Russia

NEO6860 Clinical Results to be Presented at the Pain & Migraine Therapeutics Summit

20 September 2017|Announcement| No Comments

– NEO6860 is a modality selective TRPV1 antagonist explored for the treatment of OA pain –
– A phase II PoC Study is now completed –
– NEO6860 is safe and exhibits an analgesic effect –

Montreal, September 20, 2017 – The NEOMED Institute announced today that it will present two posters on the clinical results for its lead program NEO6860 during the Pain & Migraine Therapeutic Summit, a premier pain conference covering the field of pain research and therapeutics.

POSTER #1: “NEO6860, a Modality Selective TRPV1 Antagonist: Pharmacodynamic Analysis following Intradermal Capsaicin Injection during Phase I Study” highlights and demonstrates target engagement.

POSTER # 2: “Results of a Phase II / Proof-of-concept Trial Assessing NEO6860 in Osteoarthritis Knee Pain and Dosing Considerations” highlights and demonstrates NEO6860 to be a modality selective compound resulting in analgesia without inducing hyperthermia or impaired noxious heat perception, two side effects that have halted past TRPV1 antagonist programs.

“This is a great honor for NEOMED and a perfect opportunity to showcase the progress we have made with NEO6860 for which we have been able to demonstrate very promising results to date,” declared Dan Chiche Chief Medical Officer at NEOMED.

“New safe, convenient and effective analgesic medications are desperately needed,” adds Dr. Pierre Arsenault, Principle Investigator on the Phase II study. “I am convinced that this study brings new data of major interest for the patients and the medical community, since the data provides preliminary evidence that NEO6860 acts as an analgesic without the major side effects previously seen with this class.”

The posters will be available for viewing for the duration of the Summit that will be held in San Diego, CA USA, September 27-28, 2017 and will be posted on NEOMED’s website thereafter.

About NEO6860

NEO6860, a new drug, under investigation for the treatment of osteoarthritic (OA) pain, shows potent antagonism of human TRPV1 when capsaicin is used as a stimulus in vitro, and has little or no effect against activation by low pH or heat. This profile, described as modality-selective TRPV1 antagonism, is predicted to relieve OA pain without the effects on body temperature or heat-pain threshold reported in the clinic with previous modality-nonselective TRPV1 antagonists.

About Osteoarthritis

Osteoarthritis (OA) is a musculoskeletal disorder involving degradation of joints, regularly associated with pain, which is the most debilitating symptom. OA of the knee is very common with approximately 250 million people with the condition globally. While pharmacotherapy is the cornerstone for the medical management of patients OA, there are significant limitations, in terms of efficacy as well as safety. Clinical effects of current drugs are small and limited to the first few weeks after start of treatment. In addition, there are significant risks associated with the use of current therapy, especially cardiovascular and gastrointestinal risks. A potent compound acting through a different mechanism, on a new target, would be desirable to circumvent the pitfalls of existing therapies.

About NEOMED Institute

NEOMED Institute is a not‐for‐profit organization whose mission is to bridge the gap between basic research and the commercialization of new drugs by providing industrial expertise in drug discovery and development, combined with the creation of a vibrant and sustainable life science ecosystem. NEOMED operates two fully integrated research and development campuses in Montreal: one specializing in small molecule therapeutics, and the other specializing in the development of biologics and vaccines. Both facilities function as open‐access drug discovery hubs housing independent commercial businesses (30 independent companies employing more than 300 people) and providing a dynamic environment that stimulates collaboration, innovation, and creativity. NEOMED is jointly funded by our pharmaceutical partners, the Ministère de l’Économie, de la Science et de l’Innovation du Québec, and the Networks of Centres of Excellence (NCE) of Canada. For more information, please visit our website: www.neomed.ca

For more information, please contact:

NEOMED Institute
Donald Olds
President & CEO
7171 Frederick-Banting
Montreal, Quebec, H4S 1Z9, CANADA
514-367-1212 Ext. 206
dolds@neomed.ca

Share this

Leave a Reply

Similar News

image articles
18 September 2017

PARG Inhibitor Collaboration – BioAuxilium and NEOMED

Read complete news
image articles
20 June 2017

NEOMED INSTITUTE AND GIP GENOPOLE ANNOUNCE A STRATEGIC COOPERATION AGREEMENT

Read complete news
© 2017 NEOMED Institute. All Rights Reserved. // Solutions Web Globalia